Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (752)	1/14/2003 1:42:23 PM
From: Jibacoa	Read Replies (1) \| Respond to of 1005

INGN's ADVEXIN combined with radiation showed tumor regression in Phase II Lung Ca Trial and was well tolerated. "Approximately 60% of patients' primary tumors regressed or disappeared after the combination therapy, as assessed by both biopsies and by CT scans three months after treatment. biz.yahoo.com The stock is up 29.69% on volume of 127K already close to 8X its daily average.(Upticks have been increasing in the last half hour.<g>) If the stock can close above the $3 level, it may get to test its June 2002 H at $3.50 siliconinvestor.com Of course the resistance above $5 is more important.<g> siliconinvestor.com Bernard